» Articles » PMID: 22127645

Regulation by Survivin of Cancer Cell Death Induced by F14512, a Polyamine-containing Inhibitor of DNA Topoisomerase II

Overview
Journal Apoptosis
Publisher Springer
Date 2011 Dec 1
PMID 22127645
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

F14512, an epipodophyllotoxin derivative equipped with a spermine moiety, is selectively taken up by the polyamine transport system over-active in tumor cells. F14512 was identified as a selective anticancer agent with a broad spectrum of antitumor activities and is currently undergoing phase I clinical trial in onco-hematology. However, the mechanism by which F14512 exerts its selective effects on neoplastic cells remains poorly understood. In this study, using mainly P388 leukemia cells, we showed that activation of the DNA damage response by F14512 did not induce immediate apoptosis but resulted in an early growth arrest. F14512-induced G2 arrest was accompanied by the appearance of a senescence-like phenotype (characterized by an increased β-galactosidase staining) with up-regulation of the cyclin-dependent kinase inhibitor p16, and cyclin D1. The early senescence-based cell cycle block was characterized by a marked increase of the level of the IAP protein survivin, but not cIAP2, in P388 cells as well as in three other leukemia and melanoma cell types. The Thr(34)-phosphorylated form of survivin was observed within 4 h after F14512 exposure. Inhibition of survivin by siRNA resulted in a switch from senescence-like growth arrest to apoptosis. Compared with the parental drug etoposide, F14512-induced DNA damage signaling pathway resulted in greater senescence like-growth arrest and delayed apoptosis. Collectively, our data show that senescence arrest and subsequent apoptosis are powerful mechanisms mediating the chemotherapeutic effects of F14512 and identify survivin as the molecular determinant responsible for a qualitative shift in cell fate from senescence to apoptosis upon treatment with F14512.

Citing Articles

The survival and proliferation of osteosarcoma cells are dependent on the mitochondrial BIG3-PHB2 complex formation.

Toki S, Yoshimaru T, Matsushita Y, Aihara H, Ono M, Tsuneyama K Cancer Sci. 2021; 112(10):4208-4219.

PMID: 34363714 PMC: 8486206. DOI: 10.1111/cas.15099.


Randomized, double-blind trial of F14512, a polyamine-vectorized anticancer drug, compared with etoposide phosphate, in dogs with naturally occurring lymphoma.

Boye P, Floch F, Serres F, Segaoula Z, Hordeaux J, Pascal Q Oncotarget. 2020; 11(7):671-686.

PMID: 32133044 PMC: 7041934. DOI: 10.18632/oncotarget.27461.


Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.

Leary A, Le Tourneau C, Varga A, Sablin M, Gomez-Roca C, Guilbaud N Invest New Drugs. 2018; 37(4):693-701.

PMID: 30547316 PMC: 6647401. DOI: 10.1007/s10637-018-0688-4.


Synthesis and Biological Evaluation of Novel Aromatic Imide-Polyamine Conjugates.

Li M, Wang Y, Zhang J, Xie S, Wang C, Wu Y Molecules. 2016; 21(12).

PMID: 27916902 PMC: 6273765. DOI: 10.3390/molecules21121637.


Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.

Leblond P, Boulet E, Bal-Mahieu C, Pillon A, Kruczynski A, Guilbaud N Invest New Drugs. 2014; 32(5):883-92.

PMID: 25008900 DOI: 10.1007/s10637-014-0132-3.